641615-35-2

Basic information

• Product Name: N-(2-methyl-5-nitrophenyl)-4-(5-pyrimidinyl)-2-pyrimidineamine
• Synonyms: N-(2-methyl-5-nitrophenyl)-4-(5-pyrimidinyl)-2-pyrimidineamine
• CAS NO: 641615-35-2
• Molecular Weight: 308.299
• Mol File: 641615-35-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(2-methyl-5-nitrophenyl)-4-(5-pyrimidinyl)-2-pyrimidineamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-methyl-5-nitrophenyl)-4-(5-pyrimidinyl)-2-pyrimidineamine(641615-35-2)
• EPA Substance Registry System: N-(2-methyl-5-nitrophenyl)-4-(5-pyrimidinyl)-2-pyrimidineamine(641615-35-2)

Safety Data

• Hazardous Substances Data: 641615-35-2(Hazardous Substances Data)

Upstream product

• 641615-34-1 1-(5-pyrimidyl)-3-(dimethylamino)-2-propene-1-one 
• 152460-07-6 1-(2-methyl-5-nitrophenyl)guanidine 
• 99-55-8 2-methyl-5-nitroaniline 
• 1025717-41-2 2-(2-methyl-5-nitrophenylamino)pyrimidin-4-one 
• 109299-78-7 pyrimidine 5-boronic acid 
• 10325-70-9 1-(pyrimidin-5-yl)ethan-1-one 
• 1232062-67-7 (E)-3-(dimethylamino)-1-(pyrimidin-5-yl)prop-2-en-1-one 
• 152460-08-7 1-(2-methyl-5-nitrophenyl)guanidine nitrate 

Downstream Products

• 1232061-97-0 N-[3-(4,5'-bipyrimdine-2-ylamino)-4-methylphenyl]-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indene-5-carboxamide 
• 641615-36-3 N₁-([4,5'-bipyrimidin]-2-yl)-6-methylbenzene-1,3-diamine 

Relevant articles and documents

INTERMEDIATES FOR A NOVEL PROCESS OF PREPARING IMATINIB AND RELATED TYROSINE KINASE INHIBITORS

4-Oxo-2-phenylaminopyrimidine derivatives as intermediates for synth of tyrosine kinase inhibitors, in particular imatinib and nilotinib.

AMIDE DERIVATIVE AND MEDICINE

The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula [1]: (wherein R1 represents -CH2-R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.